Monday, November 10, 2014 11:18:26 AM
While I remain high on CVM's long-term chances (sometime after 2016) and while I continue to hold shares here (but not add),... this provides a cautionary tale. CVM needs to make sure to hold costs down a it is essentially the sticker-shock of the personalized treatment that Dendreon came up with that sunk the potential of that company.
Drugmaker Dendreon files for Chapter 11 bankruptcy protection
Associated Press
By Tom Murphy, AP Business Writer
1 hour ago
http://finance.yahoo.com/news/dendreon-files-ch-11-bankruptcy-reorganization-114334635--finance.html
Prostate cancer drug developer Dendreon is seeking Chapter 11 bankruptcy protection with a plan that leads to either a sale of the company or a takeover by its lenders.
The Seattle company listed more than $664 million in total debts and $364.6 million in assets in a U.S. Bankruptcy Court filing on Monday. Its largest creditor is Bank of New York Mellon, which holds $620 million in notes.
Dendreon Corp. makes the prostate cancer treatment Provenge. It said Monday that its restructuring will allow for the continued delivery of the drug to doctors and patients. The drugmaker also said it has enough cash to support all operations during its restructuring.
The company said it has reached agreements on the terms of a financial restructuring with investors holding about 84 percent of $620 million in notes due in 2016.
The company will attempt to sell itself to a buyer that would continue to produce Provenge. If it receives no qualifying bids, the lenders will convert their debt to equity and take over Dendreon, which will become a privately held company.
The drugmaker's financial troubles stem from Provenge, its first commercial product approved by the Food and Drug Administration. Analysts expected the drug to ring up billions of dollars in annual sales after it was launched in 2010.
Likewise, Dendreon racked up debt as it bulked up to produce a drug that generates billions in revenue. But those sales never materialized. Provenge generated $283.7 million in revenue last year and $325.3 million in 2012.
Provenge, which trains a patient's immune system to fight cancer, has been hurt in part by its cost, limited benefit and reimbursement rates.
The drugmaker went through a series of staff and cost-cutting measures over the past few years after it became clear that revenue growth would take more time than it anticipated, said Executive Vice President and General Counsel Robert L. Crotty, in a declaration filed in U.S. Bankruptcy Court.
By early summer, the drugmaker realized that while it had managed to cut costs significantly, those reductions alone would not make the company "independently viable with its existing capital structure," Crotty wrote.
Dendreon warned shareholders in August about its debt load and said then that it was considering alternatives that could wipe out their ownership. The company said then that there was a "significant risk" that it would not be able to repay or refinance the 2016 notes.
The drugmaker also changed leadership last summer when it named former Discovery Labs leader W. Thomas Amick president and chief executive officer. The company had said in June that former CEO John H. Johnson planned to resign for personal reasons.
Shares of Dendreon shed most of their value Monday before markets opened, sinking 67 cents to 27 cents. The stock had slipped below $1 earlier this fall and has tumbled most of this year after closing 2013 at $2.99.
Recent CVM News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
- CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments • Business Wire • 12/22/2023 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/21/2023 09:15:39 PM
- UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer • Business Wire • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 10:25:18 PM
- CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock • Business Wire • 11/20/2023 09:15:00 PM
- CEL-SCI Announces Pricing of $5 Million Offering of Common Stock • Business Wire • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:01:26 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM